Chronic pain is a major clinical problem of which the mechanisms are incompletely understood. 27 Here we describe the concept that PI16, a protein of unknown function mainly produced by 28 fibroblasts, controls neuropathic pain. The spared nerve injury model of neuropathic pain 29 increases PI16 protein levels in fibroblasts in DRG meninges and in the epi/perineurium of the 30 sciatic nerve. We did not detect PI16 expression in neurons or glia in spinal cord, DRG and 31 nerve. Mice deficient in PI16 are protected against neuropathic pain. In vitro, PI16 promotes 32 trans-endothelial leukocyte migration. In vivo, PI16-/-mice show reduced endothelial barrier 33 permeability, lower leukocyte infiltration and reduced activation of the endothelial barrier 34 regulator MLCK and reduced phosphorylation of its substrate MLC2 in response to SNI. In 35 summary, our findings support a model in which PI16 promotes neuropathic pain by mediating 36 a cross talk between fibroblasts and the endothelial barrier leading to barrier opening, cellular 37 influx and increased pain. Its key role in pain and its limited cellular and tissue distribution 38 makes PI16 an attractive target for pain management. 39 40 41 42 43 44 45 46 47 48 49 50 3 Graphical Abstract 51 52 53 54 55 4
Abstract 26 Chronic pain is a major clinical problem of which the mechanisms are incompletely understood. 27 Here we describe the concept that PI16, a protein of unknown function mainly produced by 28 fibroblasts, controls neuropathic pain. The spared nerve injury model of neuropathic pain 29 increases PI16 protein levels in fibroblasts in DRG meninges and in the epi/perineurium of the 30 sciatic nerve. We did not detect PI16 expression in neurons or glia in spinal cord, DRG and 31 nerve. Mice deficient in PI16 are protected against neuropathic pain. In vitro, PI16 promotes 32 trans-endothelial leukocyte migration. In vivo, PI16-/-mice show reduced endothelial barrier 33 permeability, lower leukocyte infiltration and reduced activation of the endothelial barrier 34 regulator MLCK and reduced phosphorylation of its substrate MLC2 in response to SNI. In 35 summary, our findings support a model in which PI16 promotes neuropathic pain by mediating 36 a cross talk between fibroblasts and the endothelial barrier leading to barrier opening, cellular 37 influx and increased pain. Its key role in pain and its limited cellular and tissue distribution 38 makes PI16 an attractive target for pain management. Introduction 56 More than one-third of the United States population and approximately 1.5 billion people 57 worldwide face chronic pain 1 . In the United States, the costs of chronic pain are an estimated 58 30 percent higher than the combined costs of cancer, heart disorders, and diabetes 2 . 59 Treatment of chronic pain is still a major challenge and especially in view of the opioid crisis, 60 better understanding of the cellular and molecular mechanisms underlying chronic pain is 61 urgently needed. 62 We showed previously that mice deficient in G-protein coupled receptor Kinase 2 63 (GRK2) develop persistent pain in a number of models 3-6 . In a serendipitous discovery based on 64 RNA sequencing analysis of dorsal root ganglion gene expression comparing GRK-deficient and 65 WT mice, we identified peptidase inhibitor 16 (PI16) as a potential regulator of persistent pain 66 signaling. Pi16 is a poorly characterized member of the CAP (Cysteine-rich secretory proteins, 67 Antigen 5, and Pathogenesis-related 1) superfamily of proteins that is highly conserved across 68 species.
PI16 is predicted in the Conserved Domain Database 69 (https://www.ncbi.nlm.nih.gov/cdd) to have an extracellular role and to possess protease 70 enzymatic activity 7 . Very little is known about the tissue distribution and function of PI16. 71 What is known is that PI16 is expressed in cardiac fibroblasts, but PI16-deficient mice do not 72 have a cardiac phenotype 8, 9 . There is evidence that Pi16 regulates processing of the chemokine 73 chemerin 9 , cutaneous cathepsin K 10 , and of the matrix metalloprotease MMP2 in endothelial 74 cells 11 . There is no previous evidence for a role of PI16 in pain signaling. Here, we demonstrate 75 for the first time that PI16 plays a key role in chronic pain is expressed in fibroblasts in the 76 meninges of the DRG and the perineurium, but not by neurons or glia. 77 78
Results

79
Identification of Pi16 as a novel gene associated with pain 80 To identify novel pathways that regulate chronic pain, we compared gene expression profiles 81 between DRG from wild type (WT) and GRK2+/-mice at 5 h after intraplantar PGE 2 . We 82 selected this model, because WT mice recover within hours from PGE 2 -induced allodynia, 83 whereas GRK2+/-mice transition to chronic pain and show allodynia for at least 3 weeks 3-5 . 84 Only 5 differentially expressed genes (Pi16, Gm12250, Iigp1, Gbp2, Irgm2) were 85 identified in the DRG ( Figure 1A and Figure S1A ) after elimination of genes that differed by 86 genotype in the absence of PGE 2 ( Figure S2 ). Out of these 5 genes we further explored Pi16. We 87 selected Pi16 because it is a gene with unknown function in pain, is highly conserved in 88 eukaryotes and its protein sequence shares high degree of identity with human PI16. The 89 results in Figure 1B demonstrate that Pi16 mRNA expression was decreased in DRG from WT 90 mice during recovery from PGE 2 allodynia, but did not change in DRG from GRK2+/-mice who 91 developed persistent allodynia for at least 21 days after PGE 2 ( Figure 1B) . In a separate group of 92 WT mice we validated our findings and showed that Pi16 mRNA levels decrease during 93 resolution of PGE 2 -induced allodynia and return to base line levels at 48hrs after PGE2 injection 94 ( Figure S1B ).
96
Pi16 knock out mice are protected against SNI-induced pain 97 To determine the role of Pi16 in chronic pain, we used the spared nerve injury (SNI) model of 98 chronic neuropathic pain in Pi16-/-and WT mice. Male and female Pi16-/-mice were protected 99 against SNI-induced mechanical allodynia ( Figure 1C ). Mechanical sensitivity at baseline and in 100 the contralateral paw after SNI was not affected by genetic deletion of the Pi16 gene.
101
Protection of Pi16-/-mice against neuropathic pain was not due to changes in the 102 distribution of subtypes of DRG neurons or spinal cord dorsal horn neuron staining for NF200, 103 CGRP or IB4 ( Figure S3 ). The morphology and structure of myelinated and unmyelinated fibers 104 in the sciatic nerve and the density of PGP+ intra-epidermal nerve fibers also did not differ 105 between WT and PI16 KO mice ( Figure S3 ). These findings indicate that genetic deletion of Pi16 106 does not result in structural abnormalities in the peripheral nervous system. Together these 107 findings led us to conclude that Pi16 plays a key role in neuropathic pain. 108 109 PI16 is detected in fibroblasts in the meninges of the DRG and the epi/perineurium 110 We next characterized localization of PI16 protein in DRG and sciatic nerve. Interestingly, under 111 base line conditions, PI16 protein is expressed in the meningeal sheath surrounding the DRG 112 but is not detectable in DRG neurons or satellite glia ( Figure 1D and E). The meninges of the 113 DRG are continuous with the perineurium which surrounds the nerve fascicles and endoneurial 114 space 12,13 ( Figure 1D ). PI16 is clearly detectable in the epi/perineurium of the sciatic nerve, but 115 not in neurons and glia ( Figure 1F ).
117
In the meninges and epi/perineurium, PI16 is present in elongated cells with flat and 118 wavy nuclei which is a characteristic of fibroblasts, a major cell type present in dura and 119 arachnoid sheaths. Because of the high degree of heterogeneity among fibroblasts and the lack 120 of a pan-fibroblast marker, we used two different proteins to label fibroblasts; α-SMA (alpha 121 smooth muscle actin) and P4HB (collagen Prolyl 4-hydroxylase). Double-staining for PI16 and α-122 SMA or P4HB confirmed expression of PI16 exclusively in fibroblasts ( Figure 2A ). We did not 123 detect any PI16 staining in GLUT-1-positive cells in the inner layer of the perineurium (Figure   124   2B ). There is some evidence that PI16 is expressed in endothelial cells 11 , but we did not detect 125 PI16 in CD31-or CLDN1-positive endothelial cells in the DRG ( Figure 2C ). However, staining of 126 DRG showed that PI16 positive fibroblasts were closely associated with endothelial cells ( Figure   127 2C, top panel). A whole mount DRG staining to visualize spatial distribution of PI16 protein 128 showed a number of PI16-positive fibroblasts around the CD31 vascular network ( Figure 2C , 129 middle panel). PI16 is also expressed in fibroblasts in the meninges of spinal cord ( Figure S4 ). 130 We did not detect PI16 in neurons or glia in the spinal cord itself and PI16 was not detected in Figure 3B show that 137 PI16 mRNA and protein is also expressed in human DRG samples obtained during spinal surgery 138 wherein a spinal nerve root was sacrificed as the standard of care. These findings confirm that 139 expression of PI16 in DRG is conserved between mouse and human. 140 SNI significantly increased PI16 protein levels in the ipsilateral lumbar DRGs, and this increase 141 was detected both at day 8 and day 22 after SNI ( Figure 3C ). SNI also induced a marked increase 142 in PI16 protein in the ipsilateral sciatic nerve ( Figure 3C ). Sham-surgery did not affect PI16 levels 143 ( Figure S4E ). 144 Next, we determined in which cell type in DRG meninges and in the epi/perineurium PI16 is 145 increased in response to SNI. SNI markedly increased PI16 staining in the meningeal sheath of 146 the ipsilateral DRG and epi/perineurium of the nerve ( Figure 4A Figure S4F and G). 151 In the DRG and nerve, the SNI-induced increase in PI16 staining was associated with 152 increased meningeal and epi/perineurial thickness and expansion of fibroblasts which were 153 predominantly positive for α-SMA and co-expressed PI16 ( Figure 4C ). An expansion of PI16 154 positive fibroblasts was also observed around the injury site in the nerve ( Figure 5A ). After SNI, 155 different cell types, including immune cells infiltrate into the DRG and nerve. Expression of PI16 156 by a subset of memory T regulatory cells has been reported 14 . Therefore, we investigated 157 whether the infiltrating leukocytes expressed PI16. However, we did not detect any co-labeling 158 of Pi16 with the pan leukocyte marker CD45 in DRG or at the site of nerve injury, indicating that 159 leukocytes do not contribute to the increase in Pi16 expression in response to SNI ( Figure 5B ). 160 We also checked for the presence of PI16 in cells positive for chondroitin sulfate proteoglycan 161 (NG2) which labels endoneurial-fibroblasts, pericytes, and vasculature associated muscle cells 162 15, 16 . NG2 positive fibroblasts were detected in the endoneurial space and around the injury 163 site, but these cells did not contain PI16 ( Figure 5C ).
165
Pi16 is secreted in vitro by myofibroblasts 166 The SNI-induced increase in PI16 in the DRG and nerve was mainly detected in -SMA positive 167 fibroblasts. In vitro, differentiation of primary perineurial fibroblast into α-SMA positive 168 myofibroblasts using TGFβ1 increased Pi16 protein levels in these cells both intracellularly and 169 in the culture supernatant ( Figure 6A Figure 7B ). 203 Previous studies have identified two possible targets of PI16 that could contribute to 204 changes in leukocyte migration/infiltration, i.e. chemerin and MMP2 9,11 . PI16 has been 205 described to inhibit the proteolytic activation of the chemoattractant chemerin 9,11 . However, 206 we did not detect any difference in the expression of precursor-and activated-chemerin in the 207 lumbar DRGs between WT and Pi16-/-post SNI ( Figure 7C ). The matrix metalloprotease MMP2 208 regulates leukocyte movement at the site of injury through regulation of chemokines 18,19 and 209 in vitro its activity can be regulated by PI16 11 . Gelatin zymography revealed similar MMP2 210 activity in WT and Pi16-/-lumbar DRGs post SNI mice ( Figure 7D ). These findings indicate that 211 PI16 does not promote neuropathic pain via regulation of its putative targets MMP2 and 212 chemerin. 213 To identify a potential direct effect of PI16 on movement of immune cells, we tested the 214 transendothelial migration of monocytes in the presence of PI16 conditioned medium in vitro. 215 Monocytes seeded in the top chamber were allowed to migrate across a monolayer of TNF-α-216 treated endothelial cells in response to chemotactic CXCL12 in the lower chamber. CXCL12 is a 217 potent chemoattractant and our RNA sequencing data showed that it was increased in the DRG 218 in response to SNI. In the presence of PI16 conditioned medium, monocyte migration across the 219 endothelial barrier was increased ( Figure 7E ). We did not detect any effect of PI16-conditioned 220 medium on migration in the absence of the endothelial barrier or in the absence of CXCL12. 221 Opening of the endothelial barrier is a crucial step allowing influx of leukocytes to the 222 injured tissue. Our RNAseq data together with IPA analysis revealed lower levels of non-muscle Figure S3 ). 265 Thus, our findings strongly support a direct functional link between PI16 and neuropathic pain. Our data indicate that along the pain neuroaxis, PI16 is mainly produced by fibroblasts 268 in the meninges and in the perineurium. In accordance with our findings regarding PI16 269 expression profile in the DRG, published mouse single cell RNAseq data barely detected Pi16 270 mRNA in 23 out of 622 DRG neurons with reads below 100 in the majority of these 23 cells 21 . 271 We show that SNI induces expansion of predominantly -SMA-positive fibroblasts expressing 272 PI16 in the meninges and epi/perineurium as well as at the injury site (Figure 2-4) . Notably, SNI PI16 is a secreted protein that may act as a paracrine factor on anatomically closely 302 positioned endothelial cells in the DRG (Figure 2 and 6 ). We show that SNI induces expansion of 303 fibroblasts expressing the myofibroblast marker -SMA in the meninges that is associated with 304 an increase in PI16 expression as seen by Western blots and immunostaining (Figure 3 and 4) . 305 In addition, in vitro differentiation of fibroblasts into myofibroblasts in response to TGFβ1, led 306 to an upregulation and secretion of PI16 from primary fibroblasts ( Figure 6 ). Komuta et al. 2010 307 showed TGF-β1 receptor increases in the meninges following brain injury and TGF-β1 is 308 involved in activating meningeal fibroblasts 26 . Moreover, we found TGF-β1 mRNA was the How does PI16 influence the migration of leukocytes into the DRG? PI16-dependent regulation 334 of chemerin and MMP2 has been proposed and these proteins can regulate the movement of 335 immune cells and overall inflammatory load in tissues 9,11 . However, we did not detect changes 336 in the level of processed chemrin or MMP2 when comparing samples from WT and PI16-/-mice 337 under naïve conditions or after SNI (Figure 7 ). An increase in the permeability of endothelial 338 barrier is essential for the influx of leukocytes in to the tissues following nerve injury. Lim We have no conflicts of interests related to this study. indicates higher levels in GRK2+/-mice treated with PGE 2 (also see Figure S1 ). Genes that were 
